/
Oncology
Advanced Malignancies
54
Pipeline Programs↗
31
Active Trials↗
60
Companies Involved↗
Advanced Malignancies is a moderately active landscape with 54 programs across 60 companies. The most active players are Pfizer, BeiGene, BeOne Medicines. 22 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical2
Phase 118
Phase 212
Phase 322
Approved
No programs
Analysis
Modality Breakdown
71%
Small molecule
37 of 52 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 100% of 54 pipeline programs.
Analysis
Trial Status
198
clinical trials
Completed102 · 52%
Terminated44 · 22%
Recruiting20 · 10%
Unknown status10 · 5%
Active, not recruiting9 · 5%
Withdrawn8 · 4%
Other5 · 3%
Clinical Trials
Trial Activity
198 trials
Page 1 of 14
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)